Research theme for competitive and other funds (2)：
2024 - 2029 頭頸部癌の癌幹細胞を標的にした新規薬物治療の開発
2021 - 2024 Development of minimally invasive therapy focusing on the molecular mechanism of hypoxia in human papilloma virus-related head and neck cancer
Papers (105)：
HITOSHI HIRAKAWA, TARO IKEGAMI, HIDETOSHI KINJYO, YOSHIKAZU HAYASHI, SHINYA AGENA, TERUYUKI HIGA, SHUNSUKE KONDO, MASATOMO TOYAMA, HIROYUKI MAEDA, MIKIO SUZUKI. Feasibility of Near-infrared Photoimmunotherapy Combined With Immune Checkpoint Inhibitor Therapy in Unresectable Head and Neck Cancer. Anticancer Research. 2024. 44. 9. 3907-3912
Hirakawa H, Ikegami T, Touyama M, Ooshiro Y, Higa T, Higa T, Agena S, Kinjyo H, Kondo S, Kise N, et al. p16 Overexpression in Sinonasal Squamous Cell Carcinoma: Association with Human Papillomavirus and Prediction of Survival Outcomes. Journal of Clinical Medicine. 2023. 12. 21. 6861
Tanaka, K, Hirakawa, H, Suzuki, M, Higa, T, Agena, S, Hasegawa, N, Kawakami, J, Toyama, M, Higa, T, Kinjyo, H, et al. Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer. Current Oncology. 2023. 2023,. 30. 5409-5424
